Navigation Links
Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
Date:5/6/2009

New non-drug procedure for severe asthma featured in eight presentations at annual conference in San Diego

SUNNYVALE, Calif., May 6 /PRNewswire/ -- Asthmatx released today the schedule of presentations featuring its novel Alair(R) Bronchial Thermoplasty System at ATS 2009, the International Conference of the American Thoracic Society (ATS), which will take place in San Diego, Calif., May 15-20. The schedule includes the one year results from the pivotal AIR2 Trial, which was designed to evaluate the safety and effectiveness of bronchial thermoplasty delivered by the Alair System, which is an investigational procedure that may change the standard of care for millions of patients suffering from asthma.

"We're looking forward to an exciting ATS meeting with numerous scientific presentations focusing on bronchial thermoplasty and its potential to elevate the standard of care for patients suffering from severe asthma," said Glen French, CEO of Asthmatx. "The selection by the ATS Program Committee of the AIR2 data for inclusion in the late breaking clinical trials session further reflects the importance of these data to the asthma community."

The full schedule of oral and poster presentations surrounding bronchial thermoplasty at ATS 2009 include:

    Monday, May 18, 2009

    ORAL PRESENTATIONS: 1:30 - 4:00 PM

    Session B92 Mini-Symposium: New treatment approaches for asthma and
     allergy

    3:20-3:35 PM      Efficacy of Bronchial Thermoplasty (BT) in Patients with
                      Severe Asthma: The AIR2 Trial, Mario Castro, MD, St.
                      Louis, MO

    3:35-3:55 PM      "Bronchial Thermoplasty," Invited Featured Speaker:
                      Gerard Cox, MB, Hamilton, ON, Canada

    POSTER PRESENTATIONS: 8:15 AM - 4:00 PM (Authors will be at their
     respective posters from 10:45 AM -12:30 PM)

    Session B31: Asthma Therapeutics -- Studies in Humans

        -- Bronchial Thermoplasty, a Novel Therapeutic Procedure for Severe
           Asthma; A Detailed Procedure and Technique Discussion, Martin
           Mayse, MD, St. Louis, MO
        -- AIR2 Trial: Execution of a Sham-Controlled Double-Blind Study of a
           Novel Device for the Treatment of Severe Asthma, Gerard Cox, MB,
           Hamilton, ON, Canada
        -- Asthma-Related ER Visits and Hospitalizations Following Bronchial
           Thermoplasty (BT) in Patients with Severe, Symptomatic Asthma,
           Michael Wechsler, MD, Boston, MA
        -- Safety of Bronchial Thermoplasty (BT) in Patients with Severe,
           Symptomatic Asthma: Positive Safety Profile in the AIR2 Trial,
           Pallav Shah, MD, London, UK
        -- Long Term Safety of Bronchial Thermoplasty (BT): 3 year Data from
           Multiple Studies, Gerard Cox, MB, Hamilton, ON, Canada


    Tuesday, May 19, 2009

    LATE BREAKING CLINICAL TRIALS SESSSION: 1:30 - 4:00 PM

    ORAL PRESENTATION:

    2:45 - 3:10 PM    Bronchial Thermoplasty as Treatment for Severe Asthma:
                      Results of a Multicenter, Randomized, Sham-Controlled
                      Clinical Trial, Mario Castro, MD, St. Louis, MO

About Bronchial Thermoplasty Delivered by the Alair System

Bronchial thermoplasty is a novel non-drug treatment for asthma. The treatment is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair Catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the amount of airway smooth muscle that narrows the airways in patients with asthma during an asthma attack. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia and the patient returns home the same day. In the period immediately following bronchial thermoplasty, there is an expected increase and worsening of respiratory-related symptoms, which are of the type expected following bronchoscopy in patients with asthma. These typically occur within a day of the procedure and resolve on average within 7 days with standard care.

CAUTION: Alair System is an Investigational Device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.

Alair is a registered trademark of Asthmatx, Inc.

About Asthmatx

Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System from Asthmatx was awarded "Best of 2006" by Popular Science Magazine and bronchial thermoplasty was named one of the "Top Ten Medical Innovations for 2007" by the prestigious Cleveland Clinic Foundation. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com.


'/>"/>
SOURCE Asthmatx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
2. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
3. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
4. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
7. Pivotal Emory study focuses on teens at risk for psychosis
8. Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimers Monoclonal Antibody Platform
9. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
10. Pioneer(R) Surgical Technologys NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
11. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... SAN DIEGO , June 23, 2016 /PRNewswire/ ... advancing programs that address medical conditions resulting from ... that it has appointed Greg Doyle ... member of Leading BioSciences, executive management team and ... officer and chief financial officer. He will provide ...
Breaking Medicine Technology: